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Abstract
Fragile X syndrome, the leading heritable form of intellectual disability, is caused by hyper-
methylation and transcriptional silencing of large (CGG) repeat expansions (> 200 repeats)
in the 50 untranslated region of the fragile X mental retardation 1 (FMR1) gene. As a conse-
quence of FMR1 gene silencing, there is little or no production of FMR1 protein (FMRP), an
important element in normal synaptic function. Although the absence of FMRP has long
been known to be responsible for the cognitive impairment in fragile X syndrome, the rela-
tionship between FMRP level and cognitive ability (IQ) is only imprecisely understood. To
address this issue, a high-throughput, fluorescence resonance energy transfer (FRET)
assay has been used to quantify FMRP levels in dermal fibroblasts, and the relationship
between FMRP and IQ measures was assessed by statistical analysis in a cohort of 184
individuals with CGG-repeat lengths spanning normal (< 45 CGGs) to full mutation (> 200
CGGs) repeat ranges in fibroblasts. The principal findings of the current study are twofold: i)
For those with normal CGG repeats, IQ is no longer sensitive to further increases in FMRP
above an FMRP threshold of ~70% of the mean FMRP level; below this threshold, IQ
decreases steeply with further decreases in FMRP; and ii) For the current cohort, a mean IQ
of 85 (lower bound for the normal IQ range) is attained for FMRP levels that are only ~35%
of the mean FMRP level among normal CGG-repeat controls. The current results should
help guide expectations for efforts to induce FMR1 gene activity and for the levels of cogni-
tive function expected for a given range of FMRP levels.
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Introduction
Fragile X syndrome (FXS) is the leading heritable form of intellectual disability and the leading
monogenic form of autism spectrum disorder (ASD). In addition to cognitive impairment,
individuals with FXS can manifest a broad range of behavioral and psychiatric symptoms (e.g.,
hyperactivity, impulsivity, aggression, and anxiety), poor language development, seizures, and
characteristic physical features (see Reviews [1, 2–4]). In nearly every instance, FXS is caused
by expansion of a 50 noncoding trinucleotide (CGG) beyond ~200 repeats (full mutation; FM)
in the fragile X mental retardation 1 (FMR1) gene. These large CGG-repeat expansions gener-
ally lead to hypermethylation of the promoter and CGG-repeat regions, with attendant tran-
scriptional silencing and little or no expression of the FMR1 protein (FMRP) [5–8]. FMRP,
through its capacity as an RNA binding protein [9–13], plays a critical role in neuronal func-
tion by regulating the translation, transport, and stabilization of a substantial number of
mRNAs involved in the development and maintenance of synaptic connections [11, 14–22],
and through its role in the homeostatic control of systemic metabolism [1, 23]. FMRP has also
been shown to play a role in both the DNA damage response and the maintenance of genome
stability [24, 25], and in the regulation of ion channel activity through its direct interactions
with ion channel proteins [26–28]. Reduction or absence of FMRP, with resultant effects on
brain morphology and function [29–31], is thought to be directly responsible for the cognitive
and behavioral problems that are core features of the FXS phenotype [1].
For those whose FMR1 gene retains at least partial activity, the association between the
severity of intellectual disability and the degree of FMRP deficit remains ill-defined. For exam-
ple, ample evidence shows that FMRP levels are moderately diminished in both peripheral and
CNS cells that harbor FMR1 alleles in the premutation range (55–200 CGG repeats), in part
due to reduced efficiency of translation of the expanded-repeat FMR1 mRNA [32–34] and due
to the increased likelihood that the larger premutation alleles may be at least partially methyl-
ated [35]. Thus, reductions in FMRP, if of sufficient magnitude, could result in some degree of
intellectual deficit even within the premutation range [32, 36, 37]. It is also unclear to what
extent unmethylated FM alleles, which are capable of producing substantial quantities of
FMR1 mRNA [38, 39], have the capacity to produce FMRP from the expanded-repeat mRNA
due to the inefficiency of translation from RNAs containing FM CGG repeats [8]. Early studies
of individual fibroblast clones or lymphoblastoid lines suggested that FM alleles above ~300
CGG (either methylated or unmethylated) do not express FMRP [8, 14, 40, 41]. Kaufmann
et al. [42] also reported low FMRP levels (10.3 ± 1.7% of normal levels) for subjects with FM
alleles, although the FM CGG-repeat sizes were not reported. More recently, Pretto et al. [43]
observed that males with a fully methylated FM allele had essentially no FMRP expression (by
Western blot analysis). In one of their cases, a size- and methylation-mosaic male with a meth-
ylated 180 CGG-repeat allele and unmethylated ~200–270 CGG-repeat alleles had substantial
FMRP, reinforcing the idea that FM alleles under ~300 CGG repeats, if unmethylated, are still
capable of producing some FMRP.
Confounding the association between FMRP levels and intellectual deficit are numerous
reports of males described as being of average to above average intellectual level, or mildly
affected, with partially methylated alleles in the FM range [44–54]. However, part of the diffi-
culty in assessing the relationship between IQ and genotype/FMRP expression has been distin-
guishing individuals who harbor exclusively FM alleles from those who possess both FM and
premutation (PM; 55–200 CGG repeats) alleles. Indeed, newer studies have revealed that the
majority of individuals with FM alleles are mosaics for allele size, harboring both unmethylated
PM alleles and FM alleles [55–58], with such individuals retaining the capability of producing
at least some FMRP. The other confound associated with studies of FMRP after 1995 has been
FMR1 protein and IQ
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the use of the immunocytochemical method [59] to assess the presence/absence of FMRP.
Although the immunocytochemical method remains perfectly valid as a measure of fractional
inactivation (e.g., gene deletion; activation ratio in females), its use as a surrogate measure for
relative FMRP level (i.e., % FMRP(+) cells� FMRP relative level) can lead to large uncertain-
ties in FMRP levels because FMRP levels within each cell are not quantitated.
The question of how much FMR1 gene activity–and FMRP production–is possible in the
FM range is of critical importance in determining whether efforts to reactivate FM alleles [60–
69] will ultimately succeed in producing enough FMRP to have a positive effect on brain and
cognitive function. However, the more immediate question, and the focus of the current study,
concerns the relationship between cognitive ability and FMRP levels, irrespective of CGG-
repeat size: how much FMRP is necessary for borderline to average intellectual functioning?
The relevance of this question extends beyond the fragile X-associated disorders to other
forms of neurodevelopmental and neuropsychiatric dysfunction, as exemplified by lowered
FMRP levels in the brains of those with autism/ASD [70–72] and major psychiatric disorders,
including depression and schizophrenia [73, 74].
More recently, several approaches have been developed to provide more quantitative esti-
mates of FMRP levels from human cells/tissues. Iwahashi et al. [75] utilized an enzyme-linked
immunosorbent assay (ELISA) for FMRP. Using this assay, the range of FMRP detected in the
subjects with hypermethylated full-mutation alleles was 0.48% to 4.45% (n = 6) of levels
observed in control males. The highest FMRP value (4.45%) corresponded to a subject with
one of the smallest FM alleles (285 CGG repeats), adding support to the notion that only alleles
under ~300 CGG repeats are capable of producing significant amounts of FMRP. Iwahashi
et al. [76] also observed slightly higher FMRP levels (1.07% to 13.02% of control mean levels),
where the higher FMRP levels could be based on smaller unmethylated FM alleles (<300 CGG
repeats), as well as contributions from PM alleles. In aggregate, previous studies [58, 77, 78]
indicate that significant FMRP expression arises primarily from PM alleles and not from FM
alleles of greater than ~300 CGG repeats, regardless of methylation. Therefore, in discussing
cases of high IQ with moderate FMRP levels, it is highly likely that individuals may be harbor-
ing size-mosaic FMR1 alleles.
In the current work, we have applied the method of fluorescence resonance energy transfer
(FRET) [69, 79] to the study of the relationship between FMRP level and IQ in 184 cases with
CGG lengths spanning from normal to the FM range. We observed an FMRP-level threshold,
at ~70% of the mean value for those with normal CGG repeats, above which IQ no longer
depends on FMRP level. For FMRP levels that exceed ~35% of the mean FMRP level among
those in the normal CGG-repeat range, the upper 95%-ile for IQ values for the current cohort
approaches 85 (lower bound for normal IQ range), suggesting that this level of FMRP may be
sufficient for supporting its role in attaining normal intellectual functioning.
Materials and methods
Subjects
The Institutional Review Board of the University of California, Davis, approved all study pro-
tocols and written informed consent forms associated with this research. Written consent was
obtained from study subjects. The subjects of this study initially included 195 individuals (121
males and 74 females; 161 white, 1 black, 5 Hispanic/Latino, 4 multi-ethnic, 2 Asian, 2 others,
and 20 unknown) recruited to the University of California Davis Health MIND Institute’s
Fragile X Clinical and Research Center between 2007 and 2018 as participants in studies of
fragile X-associated disorders. Eleven individuals (9 males and 2 females) were subsequently
excluded based on secondary, known genetic neurodevelopmental disorders, a point mutation
FMR1 protein and IQ
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[80], and/or dysmorphic features atypical for FXS; all of those individuals had FMRP levels
within the normal range (the point mutation was detected by Western blot but not by FRET
assay) but were not used for further analyses.
Full thickness skin biopsies from the left posterior shoulder area were obtained with a 3
mm punch under local anesthesia with lidocaine. The biopsies were placed in RPMI 1640
(Gibco) culture media, stored at 4˚C, and processed within 24 hours. The samples were diced
into approximately 15 pieces under sterile conditions on a culture plate. The pieces were dis-
tributed among three culture dishes containing 60:40 RPMI 1640:Amnio MAXTM-C100 Basal
Medium (Gibco, Grand Island, NY, USA) and 15% AmnioMAXTM-C100 Supplement
(Gibco). Fibroblasts were allowed to grow out from the tissue pieces for 2–3 weeks, followed
by growth for no more than three passages. Cells were frozen down using 10% dimethyl sulfox-
ide (DMSO) in 60:40 media until needed.
IQ measures
Intellectual functioning was measured using the Wechsler Intelligence Scale for Children,
Third or Fourth Edition (WISC-III or WISC-IV; Pearson, London), or the Stanford Binet
Intelligence Scales, Fifth Edition (SB-5; Harcourt, San Antonio), for children ages 8–17 years,
and using the Wechsler Adult Intelligence Scale, Third or Fourth Edition (WAIS-III or WAI-
S-IV), or the SB-5 for adults ages 18 years and up. As the assessments spanned many protocols
and years of data collection, multiple test types and editions were used. IQ data were not
adjusted for floor effects [81, 82], since only a single individual had an IQ with a floored score
(IQ = 40).
Fibroblast culture
Fibroblast lines used for the current study were derived from biopsies performed over an
11-year period (2007–2018). The choice of dermal fibroblasts over peripheral blood cells was
made because we have found the stability of the protein is greater during isolation from fibro-
blasts than for isolation from peripheral blood mononuclear cells (data not shown), presum-
ably due to residual proteases in peripheral blood granulocytes and other lysed cell types or
contributions from PBMCs that have been damaged during the freezing process. The con-
stancy of the mean FMRP levels among normal controls across this period indicated that there
was no effect of the duration of storage on the FMRP levels produced following revival and cul-
ture. To provide an equal starting point for measurements of FMRP levels, cryopreserved
fibroblast lines were thawed and expanded in 60:40 media until 70–80% confluent, at which
time each line was frozen at 500,000 cells/ml. A 20-year-old control male fibroblast line was
used as a fiducial for all FRET plates, and FMRP levels were stable throughout the years it was
tested. Five aliquots of the fibroblast line at passage five were pooled and distributed over 10 T-
175 flasks, followed by growth until cells were 80–90% confluent, at which time cells were
pooled and frozen down at 500,000 cells/ml.
Genotyping
Genomic DNA isolation was performed on cultured fibroblast cells using the Gentra Puregene
genomic DNA purification kit (Qiagen, Redwood City, CA; catalog number 158389). One-
hundred to 250 ng of DNA was used to genotype each sample using AmplideX1 PCR/CE
FMR1 kit (Qiagen, Redwood City, CA; cat. no.158389). PCR fragments were sent for fragment
analysis on the ABI 3130xl Capillary Electrophoresis Genetic Analyzer in the College of Bio-
logical Sciences UCDNA Sequencing Facility at UC Davis. Peaks were analyzed and sized
using Peak Scanner 2 (Applied Biosystems; Foster City, CA).
FMR1 protein and IQ
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Western blot analysis
To analyze the point mutation case, 1016–15, (nominal concentrations of 8 μg and 16 μg total
protein) was determined by bicinchoninic acid (BCA) assay (Pierce; Rockford, IL; cat. no.
23225) for each sample and was run on a Criterion™ TGX Any kD™ Precast Gel (BioRad; Her-
cules, CA; cat. no. 567–1125) alongside 5 μl of Chameleon Duo Pre-stained Protein Ladder
(LI-COR; Lincoln, NE; cat. no. 928–60000) (marker) for 30 min at 25 mA and then 1.5 h at
150 V. Proteins were transferred to a nitrocellulose membrane at 30 V overnight at 4˚C. The
membrane was blocked in 1:1 PBS:Odyssey1 Blocking Buffer (LI-COR; 927–40000) for 1 h at
room temperature. Mouse anti-FMRP (Millipore; Burlington, MA; cat. no. MAB2160; Lot no.
2548166) primary antibody in blocking buffer, supplemented with 0.1% Tween-20, was
applied to the membrane at 1:5,000 overnight at 4˚C. Subsequently, IRDye1 800CW Goat
anti-Mouse (LI-COR; cat. no. 926–32210; Lot no. C50316-03) secondary antibody in blocking
buffer, supplemented with 0.1% Tween-20, was applied to the membrane at 1:20,000 for 1.5 h
at room temperature. Membrane was visualized on the LI-COR Odyssey Infrared Imager.
FRET analysis
Fibroblasts (500,000 cells/ml) were thawed and seeded overnight at 100,000 cells/well into
24-well plates with RPMI 1640. The cells were grown overnight in 5% CO2, ambient O2. At the
24-h mark, samples were rinsed with Dulbecco’s phosphate-buffered saline and lysed directly
on the plate with 50 μl 1X Cisbio Human FMRP assay lysis buffer + Roche cOmpleteTM Ultra
Protease Inhibitor Tablets (MilliporeSigma, Burlington, MA) for 2 h while rocking. FMRP
quantification utilized the Cisbio Human FMRP assay (63ADK038PEC0; Anti-FMRP-K Lot
no. 110514K; Anti-FMRP-d2; Lot no. 110514D; CisbioUS, Bedford, MA) and followed the
manufacturer’s protocol. The assay uses homogeneous time-resolved fluorescence technology,
as developed for quantification of FMRP [69, 79, 83]. The method uses two FMRP-specific
monoclonal antibodies conjugated to fluorescent dyes; the donor was labeled with Eu2+-Cryp-
tate and an acceptor designated d2. The time-resolved aspect of the assay exploits the long
fluorescence decay times of the Eu
2+
-Cryptate donor fluor, such that FRET measurements do
not occur until all sources of short-fluorescence-lifetime fluorescence (including from direct
excitation of the acceptor) have decayed. Ten microliters of protein lysate were used in either
triplicate or quadruplicate in a 384-well Opti-Plate (Perkin Elmer, Boston, MA), plus 10 μL
homogeneous time-resolved fluorescence technology pre-mixed antibodies. Samples were
incubated overnight in the dark and then read on the PerkinElmer VictorX5. Total protein
concentrations were determined using the Thermo Fisher Micro BCA Assay (Thermo Fisher;
Waltham, MA; cat. no. 23235). FMRP values were determined from interpolating FRET
expression on a standard curve using a fiducial cell line. The BCA values were used to deter-
mine the ratio of interpolated FMRP to total protein. Finally, we have assessed the accuracy of
the measurements by analyzing the coefficient of variation (CV) for each FMRP determination
[CV (%) = 100 x σ/FMRP] (S1 Fig). For FMRP values above 20% of the mean FMRP among
fibroblast lines with normal CGG repeat alleles, the CV is generally less than 20%; for FMRP
levels from 1 to 10% of the normal mean level, the CV values range from ~20–100%. That is,
for an FMRP level of 2%, a CV of 50% would represent a range of 1–3% for FMRP.
Statistical analysis
All statistical analyses of data were conducted using SAS 9.4 (SAS Institute, Cary, NC). Results
were expressed as mean ± standard deviation of mean. Group differences in means for quanti-
tative measures were determined by analysis of variance (ANOVA) by sex. Proportions were
compared between groups using Fisher’s exact test. Correlations of CGG-repeat size and
FMR1 protein and IQ
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FMRP level with IQ measures were assessed with Pearson’s correlation. Trend analyses of the
relationship of IQ against FMRP level were conducted using a locally weighted regression
(LOESS) and a piecewise linear regression, with adjustment for age and sex as needed. LOESS
is a nonparametric regression technique that smooths the dependent variable (IQ) in a moving
fashion and requires nonlinearity assumptions that are typical for conventional linear regres-
sion methods [84]. The LOESS smoothing parameter was inspected to identify the value,
which minimized error but did not overfit the data. The LOESS smoothing parameter incor-
porates both the tightness of the fit and model complexity. Root mean square error (RMSE)
and residuals were calculated for the LOESS fit across the entire data range. After LOESS fit
was performed, the LOESS smoothing curve was inspected to identify possible change points
for a piecewise linear regression through recursive partitioning to split data into two homoge-
nous subsets based on a given change point. This process was to minimize the RMSE with the
selected smoothing curve and was applied to each IQ measure. The final decision regarding
which change point for a piecewise linear model should be applied to each IQ measure was
made with consideration given to both the total RMSE and physical fit. The final piecewise lin-
ear regression chosen for each IQ measure was selected by considering the total RMSE, the
best fit of the curve, and the visual appeal of the combined LOESS and piecewise linear regres-
sion curves. Two-tailed P-values less than 0.05 were considered statistically significant as
appropriate.
Results
Demographics of the individuals providing dermal fibroblast samples for
the current study
A total of 195 fibroblast samples were cultured from punch skin biopsies from adults (74
females and 121 males). Eleven cases, with secondary known genetic neurodevelopmental dis-
orders, a point mutation in one case, and/or dysmorphic features atypical for FXS but with
normal FMRP levels, were subsequently excluded from statistical analyses, as previously men-
tioned. Descriptive statistics of the 184 participants used for this present study are presented in
Table 1. One of the 11 excluded cases (1016–15), a severely affected ten-year-old male [Full
Table 1. Descriptive statistics of patient characteristics, by sex.
Variable All Females Males P-value�
N (%) 184 72 (39%) 112 (61%)
Age 46.98 ± 21.88 46.92 ± 19.92 47.02 ± 23.15 0.9757
CGG-repeat size 90.68 ± 65.13 76.41 ± 37.18 100.14 ± 77.09 0.0185
Allele class, N 0.2429
Normal 22 9 13
Gray 11 4 7
Pre 130 55 75
Mosaic 11 2 9
Full 9 1 8
Missing 1 1 0
PIQ 100.22 ± 19.60 103.23 ± 16.95 98.28 ± 20.98 0.0976
VIQ 108.07 ± 21.15 109.21 ± 17.30 107.33 ± 23.56 0.5594
FSIQ 102.71 ± 21.86 105.11 ± 17.87 101.16 ± 24.03 0.2326
� Significance of difference between males vs. females.
https://doi.org/10.1371/journal.pone.0226811.t001
FMR1 protein and IQ
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scale IQ (FSIQ), 40; Performance (PIQ), 42; Verbal IQ (VIQ), 43] with a point mutation and a
normal CGG repeat [80], is displayed in Fig 1 but was excluded from regression analyses
because the point mutation prevented detection of the protein using the FRET assay.
The distributions of FMRP levels across allele classes are displayed in Fig 1, where all FMRP
values for normal or gray-zone (~46–54 CGG repeats) alleles for the current, relatively small
dataset, are well above the threshold value for the normal full-scale IQ (FSIQ) range; the sole
exception is a normal CGG-repeat allele that harbors a point mutation in the FMRP coding
sequence [80]. This case is interesting in that the FRET assay is unable to detect the mutant
protein even though the protein is produced at normal levels by Western (S2 Fig). A much
broader distribution is evident among PM alleles, where larger alleles are associated with lower
FMRP levels (correlation coefficient R = -0.22, P = 0.0103). FM alleles are all associated with
FMRP levels below the threshold level corresponding to FSIQ = 85 in the fitting model repre-
sented in Fig 2, in keeping with the general observation that all males with FM alleles have
some degree of cognitive impairment. An important, albeit less well-defined, allele class is that
comprising mosaic alleles, since individuals within this class often have multiple alleles with
variable proportions in PM and FM ranges, and with variable degrees of methylation of indi-
vidual alleles (Fig 1).
The FMRP-dependence of IQ is piecewise linear, with a threshold value for
FMRP-dependence approximately one SD below the normal mean level
For the current dataset, the transition from a strong dependence of IQ on FMRP to its inde-
pendence of FMRP levels occurs at a value of FMRP approximately 1 SD below its mean value
among individuals harboring normal CGG-repeat alleles (Fig 2). This relationship holds for
Fig 1. Distribution of FMRP levels within each allele class. Dashed lines indicate the values of FMRP 1 SD and 2 SD
(as indicated) below the relative mean level (= 1.0) of those with normal CGG-repeat alleles (see, also: Fig 2). Individual
1016–15 has a normal CGG repeat (21 CGG) but has a point mutation within the FMRP coding region [80] that
prevented detection by the FRET assay (See: S2 Fig).
https://doi.org/10.1371/journal.pone.0226811.g001
FMR1 protein and IQ
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Fig 2. Dependence of IQ on FMRP levels in cultured dermal fibroblasts, accounting for sex as a covariate. (A)
FSIQ, (B) PIQ, and (C) VIQ were determined using age-appropriate instruments as delineated in the Methods section.
FMRP levels were determined using FRET. All FMRP levels were normalized to the mean value of FMRP levels (= 1.0)
among individuals with normal CGG repeats, excluding the FMR1 point mutation (1016–15). Data displayed are for
FMR1 protein and IQ
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both Verbal and Performance IQs (VIQ, PIQ), as well as for FSIQ. Moreover, this piecewise
linear behavior remained intact even after adjusted for age and sex and in sex-specific analyses
(S3 Fig and S2 Table). For participants with FMRP levels below the -1 SD inflection point, IQ
measures steeply decrease with further decreases of FMRP levels. An important feature of this
dataset is that the regression line for IQ passes the lower end of the normal IQ range (IQ = 85)
at approximately 2 SD below the normal mean FMRP level and passes the cut-off for intellec-
tual disability (IQ = 70) at approximately 2.5 SD below the normal mean level of FMRP (Fig 2
and Table 2).
Discussion
In the current study, we quantified levels of FMRP in a cohort of 184 subjects using the
method of homogeneous, time-resolved FRET [83] and have related these levels to age-appro-
priate IQ measures. We found that the distribution of relative FMRP levels among normal
controls is broadly similar to equivalent distributions determined in platelets [77] and in dried
blood spots [78]. Two features of the FMRP–IQ relationship are noteworthy. First, there is a
threshold level of FMRP at approximately 70% (-1 SD) of the mean FMRP level for those with
normal CGG-repeat alleles, above which there is no further dependence of IQ on FMRP levels
—that is, a potential state of sufficiency such that further increases above the threshold do not
relate to further cognitive gain. Thus, based on this cross-sectional analysis, attempts to further
increase FMRP in normal individuals would not be expected to yield changes in cognitive pro-
cesses underlying IQ. Indeed, further increases in FMRP well beyond the normal range may
lead to behavioral dysfunction, as demonstrated in animal models [85, 86]. Second, for FMRP
levels below the threshold, there is a strong, positive relationship between FMRP levels and
cognitive abilities. Although the number of cases in this range is small in the current study, the
approximate linear relationship suggests that an FMRP level of only about one-third of the
normal mean level is sufficient to support a mean IQ level at the lower end of the normal IQ
range (= 85), and that an FMRP level of only 10–20% of normal would support a mean IQ at
the borderline level. In aggregate, these observations support the idea that even relatively mod-
est increases in FMRP, as obtained through efforts to induce its expression, could have a bene-
ficial effect on cognitive outcomes. Similar conclusions have been drawn following
introduction of FMR1 transgenes into Fmr1 knockout mice for both audiogenic seizure activ-
ity [87] and for motor/behavioral functions [88].
both males and females since there is no significant differential dependence of the regression lines on sex (P> 0.05, see
S1 Table); separate regression analyses for males and for females are displayed in S3A–S3F Fig. Symbols specify allele
classes as indicated. Plus/minus 1 SD for FMRP levels are indicated as red vertical dashed lines. Lower limit of normal
IQ (= 85) and borderline IQ (= 70) are indicated as horizontal blue and green dashed lines, respectively. The FMRP
level at which the regression line for IQ passes 85 is indicated by a vertical (blue) dashed line.
https://doi.org/10.1371/journal.pone.0226811.g002
Table 2. Piecewise regression models assessing the relationships between X = FMRP level (normalized to normal controls) and Y = IQ, and estimated FMRP levels
corresponding to IQ = 85 and 70.
IQ Measure FMRP below -1SD FMRP above -1SD
Fitted Regression Model P-value R2 value Estimated FMRP levels Fitted Regression Model P-value R2 value
IQ = 70 IQ = 85
Full Scale IQ FSIQ = 54.48 + 88.97 FMRP < 0.0001 0.481 0.174 0.343 FSIQ = 111.24–2.78 FMRP 0.6326 0.0021
Performance IQ PIQ = 55.90 + 83.32 FMRP < 0.0001 0.5063 0.169 0.349 PIQ = 105.45–0.48 FMRP 0.9274 0.0001
Verbal IQ VIQ = 65.13 + 78.68 FMRP <0.0001 0.3965 0.062 0.252 VIQ = 116.72–3.36 FMRP 0.5502 0.0033
https://doi.org/10.1371/journal.pone.0226811.t002
FMR1 protein and IQ
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A further implication of the current work is the expectation of the range of IQs within the
FM range. Among the eight males that harbored FM alleles without evidence of smaller PM
alleles, FMRP levels ranged from 0 to 21% relative of the normal mean FMRP level. The 21%
level was associated with a relatively small FM allele (250 CGG repeats) and a borderline IQ
(FSIQ = 70). The remaining individuals (FMRP = 0–15%) all had FSIQs ranging from 40 to
62. Given the small number of individuals with FM alleles, these results must be viewed as pro-
visional; however, they should serve to underscore the need for careful determination of both
FMRP levels and genotype before declaring FM alleles to be associated with IQ levels in the
normal range. IQs in the normal range for apparent FM alleles are actually more likely reflec-
tive of cryptic mosaicism, where–depending on the nature of size and methylation mosai-
cism–IQs can reach or exceed the lower level of the normal IQ range (Fig 1). This complex
issue will require larger studies of both mosaic and FM cases to establish a more quantitative
relationship between allele type and IQ, since the level of FMRP will depend not only on the
size range for multiple alleles but also the relative abundance of each allele, as well as their sep-
arate extents of methylation. Absent such studies, we feel it more appropriate to establish the
relationship between FMRP, which reflects the accumulated effects of allele types, and IQ.
The observed relationship between FMRP and IQ below the -1 SD threshold may have
implications for the general population. Our observations tentatively suggest that FMRP levels
would need to be reduced to about -2 SD from the normal mean (~34%) to have an average IQ
at the lower boundary of the normal IQ range (IQ = 85). Thus, were our current observations
to hold for much larger cohorts, we would predict that about 2–3% of the general population
would have an IQ below 85 as a consequence of lowered FMRP. Of course, there are many
causes of intellectual disability other than FXS, but we do not know the relationship of FMRP
to intellectual deficit in most of the other disorders. Admittedly, these extrapolated predictions
are highly provisional since they are based on a very small dataset; they should be viewed pri-
marily from the standpoint of encouraging larger studies. However, two points follow from
our observations. First, Bernard et al. [89] demonstrated in a normal rat model that early life
seizures reduce dendritic FMRP at/near synapses, with a corresponding shift of FMRP to the
neuronal soma, despite an apparent increase in overall hippocampal FMRP [90]. Thus, the
occurrence of early-life seizure creates a functional deficit of FMRP for synaptic functioning in
the rat, with the corresponding reduction of cognitive function. For a normal child, a single
seizure is not likely to substantially reduce cognitive strength, though in wildtype mice, single
seizures have been demonstrated to affect long-term cognitive outcomes [91]; however, for a
child whose FMRP levels are already low, early-life seizures could have a profound effect on
cognitive function, underscoring the need for aggressive treatment of seizure activity in a child
with fragile X syndrome or PM involvement. The second, broader implication of the current
study concerns the reports of reduced levels of FMRP in individuals with major psychiatric
disorders, where FMRP levels down to ~25% of normal have been observed in individuals
with schizophrenia [73, 74]. The critical question for this latter instance is whether intrinsically
low FMRP levels predispose to major psychiatric disorders or whether the processes involved
with those disorders drive a reduction in FMRP. Resolution of this issue will have important
ramifications for treatment of both psychiatric disorders and for fragile X syndrome.
In one of the most comprehensive analysis of the association between FMRP and IQ
(derived from the Wechsler scales) in 290 individuals with full or PM alleles, Loesch et al. [92]
utilized the immunocytochemical staining method of Willemsen et al. [59], which uses the
fraction of lymphocytes staining positive for FMRP as a surrogate measure for relative FMRP
concentration. As noted by Willemsen et al. [59], whereas this approach is useful for distin-
guishing individuals with FXS who do not produce FMRP from those with FMRP levels in the
normal range (cf. Fig 1B of [92]), the staining method does not measure relative FMRP levels
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per se. Not surprisingly, therefore, Loesch et al. [92] observed a very large variance in the per-
cent of FMRP-positive cells at all IQ levels, ranging from approximately 0–55% at IQ = 40 to
50–95% at IQ = 100, which diminished the portion of the variance that could be attributed to a
dependence of cognitive measures on FMRP. Many FM alleles reported in this and previous
studies are likely to be cryptic mosaics [58], where broad distributions of alleles may remain
undetected, but which in aggregate would contribute to FMRP production.
Several limitations are inherent in the current study, foremost among them being the rela-
tively small size of the sample cohort. While we believe that the general conclusions regarding
the relationship between FMRP and IQ are sound, our observations and interpretations
underscore the need for much larger sample cohorts. In this regard, because individuals were
recruited through ongoing studies of families with fragile X syndrome and associated disor-
ders, there is always the possibility of unrecognized bias both in the subjects with fragile X PM
and FM alleles, and also in terms of the characteristics of controls, some of whom are unaf-
fected (normal FMR1 gene) family members. We note in this regard that mean IQ values for
the normal controls are generally well above 100. Due to the retrospective nature of the study
and wide age range of participants, data from several different IQ tests were used. Although
these tests utilize the same scoring metric for standardization (mean = 100, SD = 15) and mea-
sure general intelligence, they vary in their coverage of subdomains of intelligence and rely on
different normative samples, and therefore systematic bias in scores is possible across tests.
This bias may have introduced some unwanted error in our analyses. Studies utilizing the
same test across all participants would likely yield stronger correlations between FMRP and IQ
scores.
Also, given that the heritability of intelligence in the general population is as high as 80%
[93], an important limitation of this and other studies examining the association between
FMRP and IQ is that they have generally not accounted for factors such as parental IQ or
shared environmental factors. For example, while a person with modest but significant reduc-
tion in FMRP may have an IQ in the broad normal range, this level of cognitive function may
be very substantially below what is expected based on mean parental IQ [42]. Dyer-Friedman
et al. [94] demonstrated that mean parental IQ was significantly associated with offspring IQ
in both normal siblings and females with the FM but not in males with the FM, possibly indi-
cating that the background environmental and genetic effects on IQ are stronger among those
with less severe deficits and more variable FMRP levels. Thus, future studies seeking to obtain
better estimates of the effects of the FMRP deficit should account for these shared factors if
possible.
Another fundamental limitation of the current work, as with many other studies of CNS-
based phenotypes (e.g., the relationship between IQ and brain FMRP levels), is the necessity of
using a peripheral measure of relative FMRP level (normalized to mean FMRP among those
with normal CGG repeats) as a surrogate for the brain relative FMRP level. This approach is
based on the lack of accessibility of the CNS measures and thus assumes that the relative
peripheral and brain FMRP levels have the same dependence on CGG repeat, and that the
CGG repeat and methylation status are comparable in peripheral and brain tissues; this latter
assumption is the basis for clinical testing for fragile X-associated disorders and is likely to be
generally but not universally true. One approach to evaluate the validity of this assumption is
to assess the magnitude of the residuals for IQ as a function of relative FMRP level. For FMRP
levels that are greater than -1 SD (Fig 2), the IQ distribution becomes independent of FMRP
level, and the residuals thus depend on other factors (e.g., background gene effects, environ-
mental factors); however, for further decreases in FMRP below -1 SD, where IQ is strongly
dependent on FMRP level, substantial differences in peripheral and brain FMRP levels would
be expected to result in larger IQ residuals. We have analyzed this issue by plotting the
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residuals (S4 Fig) as a function of FMRP, demonstrating that there is no evidence of an
increase in the residuals for IQ. This observation suggests that, at least as a first approximation,
the use of peripheral FMRP measures to gauge IQ is reasonable.
Finally, the potential implications we describe regarding whether therapeutically driven
changes in FMRP may or may not contribute to cognitive changes at different levels of FMRP
expression are based upon cross-sectional data; longitudinal data collected from individuals
over time would be needed to test the validity of these interpretations.
Supporting information
S1 Fig. Plot of the coefficient of variation (CV, %) as a function of the measurement-mean
FMRP level determined for each fibroblast sample by FRET. FMRP levels are normalized to
the groupwise mean FMRP level for fibroblasts with normal CGG repeats (designated FMRP
norm,ctrl).
(TIF)
S2 Fig. FMRP is present in normal concentrations in a fibroblast patient sample with an
FMR1 point mutation. Western blot analysis of the expression of FMRP in fibroblast lines
from male patients with a control allele (Control), control allele with a point mutation
(Point), or FM allele (Full). The control sample is the fiducial used for FRET plates in this
study. The point mutation sample is 1016–15.
(TIF)
S3 Fig. Dependence of IQ on FMRP levels in cultured dermal fibroblasts, separated by sex.
Females: (A) FSIQ, (B) PIQ, and (C) VIQ; Males: (D) FSIQ, (E) PIQ, and (F) VIQ. IQs were
determined using age-appropriate instruments as delineated in the Methods section. FMRP
levels were determined using FRET. All FMRP levels were normalized to the mean value of
FMRP levels (= 1.0) among individuals with normal CGG repeats (<45 CGG repeats), exclud-
ing the FMR1 point mutation (1016–15). Symbols specify allele classes as indicated. Plus/
minus 1 SD for FMRP levels are indicated as red vertical dashed lines. Lower limit of normal
IQ (= 85) and borderline IQ (= 70) indicated as horizontal blue and green dashed lines, respec-
tively. The FMRP level at which the regression line for IQ passes 85 is indicated by a vertical
(blue) dashed line.
(TIF)
S4 Fig. Absence of any increase in dispersion of IQ residuals for FMRP levels below -1 SD
from the mean FMRP level among normal CGG-repeat controls. (A) Males only; (B) both
males and females.
(TIF)
S1 Table. Gender-specific piecewise regression models assessing the relationships between
X = FMRP level (normalized to normal controls) and Y = IQ.
(DOCX)
S2 Table. Restrict to normal controls: Piecewise regression models assessing the relation-
ships between X = FMRP level and Y = subject IQ.
(DOCX)
S1 Raw Images. Original Western blot for S2 Fig. Western blot analysis of the expression of
FMRP in fibroblast lines from male patients with a control allele (Control), control allele with
a point mutation (Point), or FM allele (Full). The control sample is the fiducial used for FRET
plates in this study. The point mutation sample is 1016–15. Unused wells are marked with an
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“X”. Raw image was captured using Near-infrared (NIR) fluorescence on LI-COR Odyssey
(800 nm channel).
(TIF)
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